Satellos Bioscience Inc
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more
Satellos Bioscience Inc (MSCLF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.121x
Based on the latest financial reports, Satellos Bioscience Inc (MSCLF) has a cash flow conversion efficiency ratio of -0.121x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.13 Million) by net assets ($34.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Satellos Bioscience Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Satellos Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Satellos Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Satellos Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yuan High-Tech Development Co Ltd
TWO:5474
|
-0.011x |
|
AAPICO Hitech Public Company Limited
BK:AH
|
0.036x |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
-0.003x |
|
Koryx Copper Inc.
OTCQB:KRYXF
|
-0.376x |
|
BOS L ZY 10
F:967
|
N/A |
|
Pacific Century Regional Developments Limited
F:PFQ
|
-0.015x |
|
Summit State Bank
NASDAQ:SSBI
|
0.071x |
|
Malayan Flour Mills Bhd
KLSE:3662
|
0.098x |
Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.28 Million | $-17.40 Million | -0.368x | +22.19% |
| 2023-12-31 | $30.66 Million | $-14.50 Million | -0.473x | +72.12% |
| 2022-12-31 | $3.37 Million | $-5.71 Million | -1.696x | -253.19% |
| 2021-12-31 | $10.48 Million | $-5.03 Million | -0.480x | -105.32% |
| 2020-12-31 | $-183.84K | $-1.66 Million | 9.030x | -- |